ZVRA Key Statistics
High
9.99
Open
9.53
Volume
1.21M
Low
9.47
Prev. Close
9.53
Trading Value
11.78M
52-Week High
15.04
Relative Volume
0.774
Amplitude (%)
5.46%
52-Week Low
7.16
Turnover Rate
2.05%
Market Cap
563.07M
P/E Ratio (TTM)
4.42
P/E Ratio (Annual)
6.807
P/B Ratio
2.74
P/S Ratio
4.61
Earnings Per Share (EPS)
2.154
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
59.11M
Currency Unit
USD
ZVRA Price Performance
7 day
30 day
90 day
180 day
Year to date
1 Year
ZVRA Money Flow Distribution
ZVRA Daily Short Sale Volume
ZVRA Short Interest History
ZVRA Stock Snapshot
As of 2026-07-27, the Zevra Therapeutics, Inc. (ZVRA) stock price today is 9.655. Based on this price, the company has a market capitalization of $563.07M, with a P/E ratio of 4.42.
On 2026-07-27, ZVRA traded between 9.47 and 9.99. Today’s stock price is 1.95% above the daily low and 3.35% below the daily high, placing ZVRA in the lower range of its most recent trading range.
Trading volume currently stands at 1.21M, compared with an average daily volume of 1.56M. This suggests that trading activity is below its usual level than usual.
Over the past year, Zevra Therapeutics, Inc. shares have traded between 7.16 and 15.04. At today’s price, ZVRA is 34.85% above its 52-week low and 35.80% below its 52-week high.
ZVRA Related News
About ZVRA
Company Name
Zevra Therapeutics, Inc.
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchanges
Nasdaq
Number of Employees
61
Lot Size
100
Official Website
Currency Unit
USD
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Related Stocks
ZVRA FAQ
© 2026 CoinGlass, all rights reserved
